NCT05806060View on ClinicalTrials.gov

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2026

Conditions
Triple-Negative Breast Cancer
Interventions
DRUG

VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine

VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.

DRUG

nab-paclitaxel, with maintenance of capecitabine

Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.

DRUG

Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1

TPC

DRUG

VEGFR and TPC

VEGFR bevacizumab and TPC

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER